2Q21 earnings presentation

2021 vs. 2Q19 Vision Care growth driven by new product launches + + Alcon ● ● ● ● ● ● ● Strong US growth driven by new product launches Global contact lens share up second quarter in a row Strong demand for Precision 1 for Astigmatism Soft market conditions in international markets affected by COVID-19 Strong consumer and retail interest for Pataday Growth of Systane and MDPF launches Introduction of Simbrinza 1. Constant currency growth is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix. $812 $493 $319 Net Sales (USD $M) 2Q19 $888 $535 $353 2Q21 Contact lenses Ocular health (USD) (CC)¹ 9% 9% 8% 15 6% 11% 11%

View entire presentation